These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 25246035)

  • 21. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
    Kwon YS; Jeong BH; Koh WJ
    Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances in the research of heterocyclic compounds as antitubercular agents.
    Yan M; Ma S
    ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cursed duet today: Tuberculosis and HIV-coinfection.
    Tiberi S; Carvalho AC; Sulis G; Vaghela D; Rendon A; Mello FC; Rahman A; Matin N; Zumla A; Pontali E
    Presse Med; 2017 Mar; 46(2 Pt 2):e23-e39. PubMed ID: 28256380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
    Poce G; Cocozza M; Consalvi S; Biava M
    Eur J Med Chem; 2014 Oct; 86():335-51. PubMed ID: 25173852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance.
    Lohrasbi V; Talebi M; Bialvaei AZ; Fattorini L; Drancourt M; Heidary M; Darban-Sarokhalil D
    Tuberculosis (Edinb); 2018 Mar; 109():17-27. PubMed ID: 29559117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment.
    Lange C; Chesov D; Heyckendorf J; Leung CC; Udwadia Z; Dheda K
    Respirology; 2018 Jul; 23(7):656-673. PubMed ID: 29641838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Achieving STOP TB Partnership goals: perspectives on development of new diagnostics, drugs and vaccines for tuberculosis.
    Mwaba P; McNerney R; Grobusch MP; O'Grady J; Bates M; Kapata N; Maeurer M; Zumla A
    Trop Med Int Health; 2011 Jul; 16(7):819-27. PubMed ID: 21489070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human Tuberculosis. III. Current and Prospective Approaches in Anti-Tubercular Therapy.
    Sgaragli G; Frosini M; Saponara S; Corelli F
    Curr Med Chem; 2016; 23(21):2245-74. PubMed ID: 27142291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Managing TB in the 21st century: existing and novel drug therapies.
    Guy ES; Mallampalli A
    Ther Adv Respir Dis; 2008 Dec; 2(6):401-8. PubMed ID: 19124385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis.
    Ahmad S; Mokaddas E
    J Infect Public Health; 2014; 7(2):75-91. PubMed ID: 24216518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of drug resistantTB in patients with HIV co-infection.
    Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
    Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2006 Mar; 55(11):301-5. PubMed ID: 16557213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The resumption of consumption -- a review on tuberculosis.
    Ducati RG; Ruffino-Netto A; Basso LA; Santos DS
    Mem Inst Oswaldo Cruz; 2006 Nov; 101(7):697-714. PubMed ID: 17160276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Worldwide emergence of extensively drug-resistant tuberculosis.
    Shah NS; Wright A; Bai GH; Barrera L; Boulahbal F; Martín-Casabona N; Drobniewski F; Gilpin C; Havelková M; Lepe R; Lumb R; Metchock B; Portaels F; Rodrigues MF; Rüsch-Gerdes S; Van Deun A; Vincent V; Laserson K; Wells C; Cegielski JP
    Emerg Infect Dis; 2007 Mar; 13(3):380-7. PubMed ID: 17552090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data.
    Rifat D; Prideaux B; Savic RM; Urbanowski ME; Parsons TL; Luna B; Marzinke MA; Ordonez AA; DeMarco VP; Jain SK; Dartois V; Bishai WR; Dooley KE
    Sci Transl Med; 2018 Apr; 10(435):. PubMed ID: 29618565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TMC207 becomes bedaquiline, a new anti-TB drug.
    Palomino JC; Martin A
    Future Microbiol; 2013 Sep; 8(9):1071-80. PubMed ID: 24020736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
    Centers for Disease Control and Prevention (CDC)
    MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
    Pym AS; Diacon AH; Tang SJ; Conradie F; Danilovits M; Chuchottaworn C; Vasilyeva I; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; Van Baelen B; van Heeswijk RP; Dannemann B;
    Eur Respir J; 2016 Feb; 47(2):564-74. PubMed ID: 26647431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
    Pontali E; Visca D; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
    Curr Opin Pulm Med; 2018 May; 24(3):244-252. PubMed ID: 29470252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.